Additional analysis related to the primary endpoint in the CD34+ cell group showed CP score and class improvement in 5 of the 10 patients (50%) and improvement from decompensated to compensated cirrhosis in 4 (40%) at 24 weeks post-enrollment. The gene discussed is CD34; the disease is Cirrhosis.